NEW YORK (GenomeWeb) — Data presented earlier this month at the 2014 European League Against Rheumatism (EULAR) Annual Congress by Crescendo Bioscience has added upon earlier retrospective data supporting the clinical utility of the company's Vectra DA test in measuring disease activity and predicting joint damage in rheumatoid arthritis patients.

Presentations also provided the first evidence that the multi-protein biomarker test may also be able to predict response to different second-line therapies in patients who appear, clinically, to be unresponsive to methotrexate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.